TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15291378
Drug: Olmesartan 10
Normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 10 mg/d
Study: 11997274
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg/d)
Study: 2093382
Drug: Trimetazidine 60
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 60 mg per day
Study: 24261811
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination with a minimum immunizing dose of BRSV (experiment 1)
Study: 24261811
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination with a commercially available combination modified-live virus vaccine (experiments 2 and 3)
Study: 24261811
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination (experiments 1, 2, and 3)
Study: 17551835
Drug: Bowman-Birk inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowman-Birk inhibitor concentrate (BBIC) for 12 weeks
Study: 17242499
Drug: Oral prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisone, 40 mg/day for 7 days
Study: 17242499
Drug: Intramuscular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular triamcinolone LA, 40 mg/day for 3 days
Study: 12540390
Drug: L. helveticus
Normalized name: L. helveticus,rhamnosus/B. longum/zinc yeast/selenium yeast 2 billion cell-2 mg-12.5 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. helveticus LBK‐16H fermented milk (150 mL/d)
Study: 8861533
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily intravenously for 2-4 days followed by oral doses of 400 mg for up to 10 days
Study: 8861533
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg twice daily intravenously for 2-4 days followed by oral doses of 2 x 500 mg for up to 10 days
Study: 6366124
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP)
Study: 6366124
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (C‐MOPP)
Study: 6366124
Drug: Involved field,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy
Study: 28254107
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment to both the MTrP and distal points using a deactivated acupuncture laser device
Study: 25790807
Drug: Non-diuretic antihypertensive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diuretic antihypertensive drugs
Study: 19205490
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (proxymetacaine eye drops)
Study: 15307520
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC‐‐Migpriv)
Study: 15307520
Drug: Ergotamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine plus caffeine (2 mg ERG + 200 mg CAF‐‐Coffecorn forte)
Study: 8310757
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (two doses at day 0, one dose at day 21)
Study: 8310757
Drug: Schedule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B (one dose at days 0, 10 and 21)
Study: 2874755
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no prophylactic therapy)
Study: 28699054
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy (CBT)
Study: 30946210
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg twice a day for 12 weeks)
Study: 30946210
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid (mometasone furoate nasal spray for 12 weeks)
Study: 30946210
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Erythromycin and Intranasal steroid)
Study: 23995774
Drug: Cocaine vaccine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine vaccine
Study: 16572918
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg (test formulation)
Study: 12174784
Drug: Parenteral analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral analgesics or tranquillizers
Study: 9850348
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 micrograms twice daily)
Study: 9850348
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms twice daily)
Study: 2531051
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide and fenoterol nebulizer solutions
Study: 2531051
Drug: Fenoterol nebulizer
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol nebulizer solution
Study: 26004151
Drug: Glucocorticosteroid (GS)
Normalized name: GS 0573
DrugBank: GS 0573 (DB08843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroid (GS) treatment
Study: 20722677
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg)
Study: 19273705
Drug: Thalidomide consolidation
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide consolidation therapy for 12 months
Study: 19273705
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with indefinite prednisolone maintenance therapy
Study: 11871585
Drug: Nurse-administered self-efficacy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered self-efficacy intervention given on five monthly occasions
Study: 9924367
Drug: Dorzolamide (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide (topical carbonic anhydrase inhibitor, three times daily, one eye)
Study: 9924367
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle treatment)
Study: 26827067
Drug: Tapered MIS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapered MIS® Seven implants (TI)
Study: 26827067
Drug: Cylindrical Astra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical Astra® Osseospeed implants (CI)
Study: 24866311
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment strategy
Study: 22960434
Drug: Armodafinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (250 mg)
Study: 24267731
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/day
Study: 20222840
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/day plus r-FSH (37.5 units/day)
Study: 20222840
Drug: Myo-inositol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (4 g) plus folic acid (400 microg) daily
Study: 18258384
Drug: Concomitant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant temozolomide (TMZ) at 50 mg/m² (Group A)
Study: 18258384
Drug: Concomitant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant temozolomide (TMZ) at 75 mg/m² (Group B)
Study: 15920447
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with 2 g amoxicillin 1 hour before every appointment (n=23)
Study: 15920447
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n=24)
Study: 12829663
Drug: 12 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of single-agent paclitaxel administered every 28 days
Study: 12829663
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of single-agent paclitaxel administered every 28 days
Study: 10390255
Drug: Dexamethasone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.25 mg/kg bid for 3 days, then 0.15 mg/kg bid for 3 days, followed by a tapering schedule to 0.1 mg/kg until 42 days)
Study: 6833676
Drug: Atropine pretreatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine pretreatment followed by high doses of methacholine
Study: 6833676
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (40 mg) pretreatment
Study: 24966097
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of PS + N-acetylcysteine (NAC)
Study: 24966097
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of SB + NAC
Study: 22306907
Drug: GC (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC (gemcitabine and cisplatin chemotherapy alone)
Study: 20410684
Drug: PBTM-DM group
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBTM-DM group (pantoprazole 40 mg b.i.d., bismuth citrate 400 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg b.i.d. for 14 days)
Study: 20410684
Drug: PCA-DM group
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA-DM group (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 14 days)
Study: 20410684
Drug: PBTM-non-DM group
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBTM-non-DM group (quadruple therapy for 14 days)
Study: 18545194
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise (REX) with unloaded leg on an inertial resistance ergometer and albuterol (16 mg.d)
Study: 15503297
Drug: Ifosfamide (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (10 microg/kg/day)
Study: 15503297
Drug: Ifosfamide (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (5 microg/kg/day)
Study: 15503297
Drug: Ifosfamide (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (5 microg/kg/day) and IL‐6 (2.5‐5 microg/kg/day)
Study: 12425706
Drug: Self-administered behavioral
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered behavioral treatment using a self-help booklet (control condition; n = 75)
Study: 10512900
Drug: C pneumoniae-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: C pneumoniae-specific IgG or IgA antibodies
Study: 10512900
Drug: Antibody titers
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody titers
Study: 10512900
Drug: C pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: C pneumoniae IgG titer in combination with high Lp(a) level
Study: 6171898
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 12 mg per kg daily of 5‐FU for four consecutive days, then 6 mg per kg on alternate days to the point of toxicity or to a maximum of five doses, followed by 12 mg per kg weekly for one year
Study: 88753
Drug: 5‐FU chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU chemotherapy
Study: 24857044
Drug: Gemcitabine (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (at any time during study treatment)
Study: 15936560
Drug: Breast-conservation therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conservation therapy (BCT)
Study: 12658913
Drug: Risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4 mg/day) or Olanzapine (10 mg/day)
Study: 8874658
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 500 micrograms bid
Study: 22189827
Drug: cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine A 0.05% eye drops (one drop twice daily)
Study: 17582281
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/d
Study: 17582281
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/d (after titration)
Study: 17582281
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 mg/d
Study: 10195533
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg meperidine
Study: 10195533
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg meperidine
Study: 10195533
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg meperidine
Study: 10195533
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg meperidine
Study: 10195533
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg meperidine
Study: 7594664
Drug: PncOMPC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncOMPC vaccine (tetravalent pneumococcal conjugate vaccine)
Study: 6104131
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin given by mouth in therapeutic doses
Study: 6104131
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy without specific drug treatment
Study: 31025924
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of subcutaneous NTK
Study: 31025924
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of subcutaneous NTK
Study: 31025924
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of subcutaneous NTK
Study: 25224929
Drug: IM twice/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM twice/day (α1-blocker + 0.1 mg imidafenacin twice daily)
Study: 25224929
Drug: IM nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM nightly (α1-blocker + 0.1 mg imidafenacin nightly)
Study: 25224929
Drug: Control (α1-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (α1-blocker alone)
Study: 19926098
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment started early
Study: 19926098
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment started late
Study: 17707720
Drug: Gestrinone 5
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 5 mg administered orally before ovulation (Group A)
Study: 17707720
Drug: Gestrinone 5
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 5 mg administered orally after ovulation (Group B)
Study: 17707720
Drug: Gestrinone 5
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 5 mg administered (both groups)
Study: 9865208
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy photon therapy (LEPT)
Study: 8560536
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine, 2 doses, 2 weeks apart
Study: 8560536
Drug: Escherichia coli
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli K12 placebo, 2 doses, 2 weeks apart
Study: 8560536
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine
Study: 2482650
Drug: RU 486,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486, 25 mg twice daily for 4 days (Group I)
Study: 2482650
Drug: RU 486,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486, 25 mg for 3 days (Group II)
Study: 2482650
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of sulprostone, 0.25 mg on the last day of RU 486 treatment
Study: 26446696
Drug: Single training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single training of GPs in the pharmacological management of HF drug therapy according to ESC guidelines
Study: 23414504
Drug: Cocaine cholera
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine cholera toxin B conjugate vaccine
Study: 15281472
Drug: Butterbur, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur, 50 mg twice daily
Study: 8214745
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate (1.5 mg/kg)
Study: 11590533
Drug: GW420867X 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 50 mg/day
Study: 11590533
Drug: GW420867X 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 100 mg/day
Study: 11590533
Drug: GW420867X 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 200 mg/day
Study: 11590533
Drug: GW420867X (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X (all doses combined)
Study: 24967813
Drug: Maternal 25‐OHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal 25‐OHD deficiency (<37.5 nmol/L)
Study: 20627974
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=127) attended four interactive group sessions and received monthly support via text messages for 12 months
Study: 18662191
Drug: Ranolazine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (45 mg/h for 3 hours followed by 90 mg/h for 5 hours)
Study: 15744450
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium mineral water (HCaMW) - 1 liter daily (596 mg Ca/l)
Study: 15744450
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 1 liter of mineral water with low calcium content (10 mg/l)
Study: 11796428
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone for 3 months followed by inhaled budesonide for 15 months (800 microg bid)
Study: 10732870
Drug: BCNU 120
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU 120 mg/m2 d.l, VP 16 60 mg/in2 d.2‐4, procarbazine 85 mg/m2 d. 2‐8 (Arm A)
Study: 10732870
Drug: Mitoxantrone 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 6 mg/m2 d.l with VP16 and procarbazine in the same dosage and schedule (Arm B)
Study: 6941445
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of tinidazole administered 8-15 hours before the abortion
Study: 31321428
Drug: Breakfast of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast of oats and milk (431 kcal; 65 g carbohydrate, 11 g fat, 19 g protein) followed by rest (BR)
Study: 24304626
Drug: Reflexology therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology therapy for 30 minutes on feet, hands, and ears for 5 days
Study: 24304626
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no reflexology therapy)
Study: 24304626
Drug: Reflexology therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology therapy
Study: 17464992
Drug: Clevudine 30
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 30 mg once daily for 24 weeks
Study: 11296078
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac (0.5 to 1 mg/kg) and IV fluids
Study: 25735565
Drug: Socket augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socket augmentation
Study: 24161288
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: MP (2 mg/kg) after lidocaine (0.6 mg/kg) with a tourniquet with arm down (venous engorgement)
Study: 19698996
Drug: Caffeine-free solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-free solution
Study: 10978039
Drug: Piracetam (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2400 mg twice daily)
Study: 7979565
Drug: Periconceptional multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periconceptional multivitamin supplementation including 0.8 mg folic acid
Study: 6375276
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide twice daily
Study: 25890835
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (D4 and D6)